News articles about Cyberonics (NASDAQ:CYBX) have trended positive this week, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Cyberonics earned a news impact score of 0.41 on Accern’s scale. Accern also gave news articles about the medical device company an impact score of 44.9052519722059 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

WARNING: “Positive Press Coverage Somewhat Unlikely to Affect Cyberonics (NASDAQ:CYBX) Stock Price” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this article on another website, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The original version of this article can be viewed at https://www.watchlistnews.com/positive-press-coverage-somewhat-unlikely-to-affect-cyberonics-nasdaqcybx-stock-price/1469415.html.

About Cyberonics

Cyberonics, Inc is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD).

Receive News & Ratings for Cyberonics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyberonics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.